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Abstract
Highly promising preclinical data obtained in cultured cells and in nude mice bearing xenografts contrast with the rather modest
clinical efficacy of Polo-like kinase 1 (Plk1) inhibitors. In the present study, we investigated if Plk1 might be a suitable target in
hepatocellular carcinoma (HCC) and if a genetically engineered mouse tumor model that well reflects the tumor cell and micro-
environmental features of naturally occurring cancers might be suitable to study anti-Plk1 therapy. Analysis of Plk1 expression in
human HCC samples confirmed that HCC express much higher Plk1 levels than the adjacent normal liver tissue. Inhibition of Plk1
by an adenovirus encoding for a short hairpin RNA against Plk1 or by the small-molecule inhibitor BI 2536 reduced the viability of HCC
cell lines and inhibited HCC xenograft progression in nude mice. Treatment of transforming growth factor (TGF) α/c-myc bitransgenic
mice with BI 2536 during hepatocarcinogenesis reduced the number of dysplastic foci and of Ki-67–positive cells within the foci,
indicating diminished tumorigenesis. In contrast, BI 2536 had no significant effect on HCC progression in the transgenic mouse
HCCmodel as revealed bymagnetic resonance imaging.Measurement of BI 2536 bymass spectrometry revealed considerably lower
BI 2536 levels in HCC comparedwith the adjacent normal liver tissue. In conclusion, low intratumoral levels are a novel mechanism of
resistance to the Plk1 inhibitor BI 2536. Plk1 inhibitors achieving sufficient intratumoral levels are highly promising in HCC treatment.
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Introduction
Hepatocellular carcinoma (HCC) is the fifth most frequent malig-
nant neoplasm worldwide and, owing to the lack of effective treat-
ment options, is the third leading cause of cancer-related mortality
[1]. HCC is often diagnosed at an advanced stage when it is no longer
amenable to curative therapies. Alterations in the endogenous tumor
suppressor networks seem to contribute to the resistance of HCC
to classic cancer chemotherapies because the activity of most con-
ventional chemotherapeutic agents highly depends on innate pro-
apoptotic pathways that are disabled in HCC [2]. Other mechanisms
of chemotherapy resistance of cancers are related to the tumor micro-
environment [3].
The efficacy of drugs against solid tumors such as HCC is limited
by resistance and toxicity resulting from the action on nontumor
cells. Therefore, large efforts are under way to identify molecules,
the inhibition of which preferentially kills malignant cells. The
mitosis-associated serine/threonine kinase Polo-like kinase 1 (Plk1) is
a good candidate to fulfill this condition [4]. Thus, most malignancies
show higher Plk1 expression than their normal counterparts, and
inhibition of Plk1 results in spindle dysfunction, mitotic checkpoint
activation, G2-M phase arrest, and apoptosis in cancer cells [4]. High
Plk1 expression has also been reported in HCC, and the suppression
of Plk1 expression by RNA interference (RNAi) reduced the prolif-
eration of HCC cells [5–7], suggesting that Plk1 might be a suit-
able target in HCC. Interestingly, there is evidence that cancer cells
might be more sensitive to Plk1 inhibition than primary nontrans-
formed cells [8–13]. These results have prompted the development
of Plk1-specific small-molecule inhibitors, some of which are cur-
rently in clinical trials [14]. Plk1 inhibitors such as BI 2536 show
high efficacy in cultured tumor cells and nude mice tumor xeno-
grafts. However, clinical trials in patients with different tumor
entities revealed only modest clinical efficacy, hematotoxicity be-
ing dose-limiting [14]. Obviously, these preclinical tumor models
do not faithfully predict or recapitulate the clinical efficacy of the
Plk1 inhibitor.
In genetically engineered mouse (GEM) tumor models, the spon-
taneous and unconstrained way in which such tumors evolve well
reflects both the tumor cell and microenvironmental features of nat-
urally occurring cancers [15–17]. GEM tumor models may better
predict therapy outcome compared with nude mice bearing trans-
planted tumors has been provided for pancreatic ductal carcinoma
and non–small cell lung cancer [18,19], but this has not yet been
examined for HCC, and GEM tumor models have not yet been
used to examine Plk1-directed therapeutics. To investigate if Plk1
indeed might be a suitable target in HCC and to explore if a GEM
HCC model are suitable to study anti-Plk1 therapy, we here com-
pared the therapeutic efficacy of Plk1 inhibition by RNAi as well as
the Plk1 inhibitor BI 2536 in cultured HCC cells, nude mice xeno-
grafted with HCC, and in a transgenic mouse model (transforming
growth factor (TGF)α/c-myc) developing HCC endogenously. Our
data support the contention that Plk1 is a highly promising target in
HCC and that TGFα/c-myc mice are suitable to study anti-HCC
therapy. The Plk1 inhibitor BI 2536 inhibited hepatocarcinogenesis
but was ineffective in HCC in TGFα/c-myc mice. Measurement of
BI 2536 concentrations revealed much lower levels in the tumors
compared with the normal liver tissue, which may explain the lack
of efficacy of BI 2536 in HCC of TGFα/c-myc mice. Thus, insuf-
ficient drug levels might be a mechanism of primary resistance
in HCC.
Materials and Methods
Cell Culture
Huh-7 cells (kindly provided by K. Breuhahn, University of
Heidelberg) were grown in RPMI 1640 medium supplemented
with 10% fetal calf serum and penicillin/streptomycin (Invitrogen,
Carlsbad, CA).
Nude Mice Experiments
All animal experiments were approved by the local Animal Care
Committee and were in agreement with German legal requirements.
A total of 8 × 106 Huh-7 cells (resuspended in 150 μl of phosphate-
buffered saline [PBS]) were injected subcutaneously into the flanks of
CD1 nude mice (Charles River, Wilmington, MA). When the tumors
reached a diameter of 2 to 3 mm, 7 × 109 plaque-forming units (pfu)
of adenoviral suspensions (AdV control or AdV-Plk1) were slowly
injected into the tail vein. Each treatment group consisted of seven
mice. Body weight and tumor size were determined every 3 days.
At the end of the experiment, the mice were sacrificed by cervical dis-
location. Tumors were excised, weighed, and snap frozen at −80°C
until further use.
To study the effect of BI 2536 (kindly provided by Boehringer
Ingelheim, Vienna, Austria, or was purchased from Axon, Groningen,
the Netherlands) on Huh-7 xenograft progression in nude mice, animals
with established tumors received 30 mg/kg BI 2536 twice per week.
Body mass and tumor size were measured and recorded.
To determine the rate of infection of the Huh-7 tumors with in-
travenously administered AdV, mice harboring 2 to 3 mm tumors
received 7 × 109 pfu of AdV-LacZ or AdV control. After 72 hours,
the tumors were excised and 7-μm-thick cryosections were produced.
The sections were fixed in fixative solution (0.5% glutaraldehyde in
MgCl2-PBS solution) for 20 minutes. Subsequently, the sections were
rinsed twice in PBS and incubated in 5-bromo-4-chloro-3-indolyl-β-
D-galactopyranoside (X-Gal) staining solution (InvivoGen, San Diego,
CA) for 45 minutes at 37°C, followed by rinsing four times with PBS.
Counterstaining was performed with Nuclear Fast Red (0.1% in 5%
Al2(SO4)3) (Sigma-Aldrich, St. Louis, MO).
Transgenic Mice Experiments
Male TGFα/c-myc bitransgenic mice were produced by crossing
homozygous metallothionein/TGFα and albumin/c-myc single trans-
genic mice in CD13B6CBA background as described [20,21]. To min-
imize bias from interindividual variation, littermates were assigned to
the two treatment groups. Directly after weaning, the mice received
ZnCl2 to induce the expression of TGFα and thereby accelerate
hepatocarcinogenesis. The body weights were recorded during the
treatments. To study the effect of BI 2536 on hepatocarcinogenesis,
the mice received either BI 2536 (30 mg/kg) or PBS intravenously
twice weekly from week 12 to 16 after beginning of the zinc induc-
tion. The whole livers from the TGFα/c-myc mice were fixed in 4%
neutral formalin at 4°C overnight. Pieces of 1 to 1.5 g of liver were
examined histopathologically.
To study the effect of BI 2536 on HCC progression, TGFα/c-myc
mice were induced with ZnCl2 for 20 to 23 weeks. To detect and
monitor the endogenously formed HCCs in the TGFα/c-myc mice,
contrast-enhanced magnetic resonance imaging (MRI) using gadoxetic
acid contrast agent (Primovist, Bayer-Schering, Berlin, Germany) and
a 3-T MRI scanner (Siemens Magnetom Trio, Siemens Medical Solu-
tions, Erlangen, Germany). Before imaging, animals were anesthetized
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using ketamine (70 mg/kg) and xylazine (12 mg/kg), injected with
gadoxetic acid (0.057 mmol/kg), and positioned in the scanner. The
imaging sequences included T1-weighted sequences with following
parameters: echo time = 20 milliseconds, repetition time = 947 milli-
seconds, field of view = 100 mm, slice thickness = 1 mm, flip angle =
140°, fat suppression = fat saturated. All animals were imaged in the
axial plane.
Two weeks after the first tumor detection, mice received another
MRI and tumor progression was determined. Mice with verified tu-
mors received 30 mg/kg BI 2536 twice per week for 4 weeks. At the
end of treatment, the tumor size was again measured by MRI.
All analytic procedures and additional methods are described in
the Supplementary Materials and Methods.
Results
Validation of Plk1 as Target in HCC
Plk1 is a promising target for cancer therapy [4]. Small-molecule
Plk1 inhibitors are currently examined for their efficacy in several
cancer entities, but the feasibility of using small-molecule inhibitors
for HCC has not yet been investigated. We initially confirmed recent
findings [5–7] that most HCC express considerably higher levels of
Plk1 at the mRNA and protein levels compared with the surround-
ing normal liver tissue (Figure W1).
To investigate whether Plk1 inhibition might be an effective strat-
egy to inhibit HCC, we studied the effect of BI 2536 as well as of an
adenoviral vector driving the expression of an optimized short hairpin
(sh)RNA against Plk1 (AdV-Plk1) on the viability of HCC cell lines.
BI 2536 as well as AdV-Plk1, but not an adenovirus encoding a con-
trol short hairpin RNA (shRNA) (AdV control), reduced the viability
and increased apoptosis of Huh-7 cells (Figure 1, A, B, E , and F ). We
confirmed that AdV-Plk1, but not AdV control, decreased Plk1 ex-
pression (Figure W2). Similar data were obtained in three other HCC
cell lines (HepG2, Hep3B, and PLC/PRF/5; data not shown). We
also checked if BI 2536 and AdV-Plk1 elicit the characteristic effects
of Plk1 inhibition, that is, mitotic G2-M phase arrest and monoastral
spindles in Huh-7 cells by fluorescence-activated cell sorting (FACS)
and immunocytochemical analyses. Indeed, BI 2536 as well as AdV-
Plk1, but not AdV control, strongly increased the amount of cells with
4N and elicited monoastral spindles (Figure 1, C , D, G , and H).
Next we studied the effects of BI 2536, AdV-Plk1, and AdV control
on the progression of Huh-7 xenografts in nude mice. To this end, BI
2536 or PBS was injected intravenously into nude mice bearing Huh-7
cell tumors twice weekly. The size of the tumors was measured 4, 7, and
11 days after the beginning of treatment. As illustrated in Figure 2A,
treatment of nude mice bearing Huh-7 xenografts with BI 2536 clearly
inhibited the progression of the xenografts (P < .05).
To investigate the effect of RNAi-induced suppression of Plk1
expression on the progression of Huh-7 xenografts in nude mice, we
first determined the ability of systemically administered AdV to effec-
tively infect Huh-7 xenografts in nude mice. AdV-LacZ or vehicle as a
control was injected intravenously into Huh-7 tumor-bearing nude
mice. Three days later, the tumors were excised and 50 histologic
sections were examined for the presence of β-galactosidase by X-Gal
staining. About 10% to 70% of the tumor cells from AdV-LacZ–treated
animal showed positive X-Gal staining (Figure W3, middle and right
panels). The tumors of saline-injected animals were analyzed and found
not to contain positive X-Gal–stained cells (FigureW3, left panel). These
data indicated that the Huh-7 tumors in the nude mice were infected to
a considerable extent on intravenous administration of AdVs.
We next evaluated whether systemic administration of AdV-Plk1
reduced HCC tumor progression in the Huh-7 xenograft mouse model.
To this end, AdV-Plk1, AdV control or PBS were injected once intra-
venously into nude mice bearing Huh-7 cell tumors (as performed
above with AdV-LacZ). The size of the tumors was measured every
3 days for a period of 1 month. The tumors in AdV-Plk1–treated mice
grew slower than tumors in AdV control–treated animals, whereas AdV
control had no significant effect (Figure 2B), verifying that the growth
inhibitory effect of AdV-Plk1 was specific for the Plk1-shRNA encoded
by the AdV and not by the AdV infection itself.
To investigate if the inhibitory effect of AdV-Plk1 on HCC tumor
progression was due to Plk1 depletion, Huh-7 tumors were excised 3,
4, 7, or 14 days after injection of the virus into the mice and analyzed
for Plk1 expression by immunoblot analysis. As shown in Figure 2C ,
the Plk1 levels were reduced in tumors from AdV-Plk1–treated mice
compared with animals that received the control virus. Reduced Plk1
protein expression was detectable up to 7 days after administration of the
AdV to the animals, whereas 14 days after injection, down-modulation
of Plk1 expression was not detectable any more. Analyses of the tumor
extracts for an apoptotic marker (cleaved poly[ADP-ribose] polymerase
[PARP]) by immunoblot analysis revealed the emergence of cleaved
PARP fragment in tumor extracts from AdV-Plk1–treated mice, but
not in tumors from AdV control–treated animals (Figure 2C), suggest-
ing that AdV-Plk1, but not AdV control increased the rate of apoptosis
in the HCC tumors. Together, these data indicate that inhibition of
Plk1 activity by BI 2536 or suppression of Plk1 expression by RNAi
caused similar anti-HCC effects in cultured HCC cell lines and
Huh-7 xenografts.
Figure 1. BI 2536 as well as AdV-Plk1 decreased the viability of cultured Huh-7 cells. (A, B) BI 2536 dose-dependently decreased the
viability of Huh-7 cells. Huh-7 cells were exposed to the indicated concentration of BI 2536. After 48 hours, the viable cell mass was
analyzed by the MTT test (A), the amount of apoptotic cells was detected after 24 hours by Hoechst staining (B). Bars signify means ±
SD of duplicates. For each condition, at least 1400 cells were evaluated. (C) BI 2536 elicited G2-M arrest. Huh-7 cells were exposed to BI
2536 for 30 hours, followed by FACScan analysis. Cells with subgenomic DNA content were not gated. (D) BI 2536–treated Huh-7 cells
show monoastral spindles. The cells were treated with BI 2536 (10 nM) for 2 days and stained for α-tubulin and DNA. (E, F) AdV-Plk1
reduced the viability of Huh-7 cells. The cells were infected with 105 pfu/ml of AdV-Plk1 or AdV control. After the indicated time, the
viable cell mass was analyzed by the MTT test (E). (F) AdV-Plk1 increased the amount of apoptotic cells, whereas AdV control did not. At
24 hours after treatment with AdV-Plk1 or AdV control, the number of apoptotic cells was determined. Bars signify means ± SD of
five independent determinations. The values were significantly different between AdV control and AdV-Plk1–treated cells (*P > .05).
(G) FACScan analysis of Huh-7 cells performed 30 hours after infection with AdV-Plk1, AdV control, or no treatment. Cells with subge-
nomic DNA content were not gated. AdV-Plk1, but not AdV control, elicited an increase in the amount of cells with 4N. (H) Phenotype of
Huh-7 cells treated with AdV-Plk1 (105 pfu/ml). α-Tubulin immunostaining is shown in red; DNA is shown in cyan. AdV-Plk1 treatment
elicited monoastral spindles.
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BI 2536 Has No Significant Effect on HCC Progression
in TGFα/c-myc Mice
Because of the limited predictability of cell culture and tumor
xenograft models for clinical efficacy, including tumor xenograft mod-
els for Plk1-targeting therapeutics, and the evidence for superiority of
certain GEM to nude mice tumor models with respect to predicting
clinical outcome in other cancer entities, we investigated Plk1 targeted
therapy in the TGFα/c-myc–driven HCC mouse model. Aberrant
expressions of c-myc as well as TGFα are frequent in primary human
HCCs [22–24], and the TGFα/c-myc–driven hepatocarcinogenesis
models quite closely resemble various histopathologic, biochemical,
and cytogenetic features characteristic of human liver oncogenesis
[21]. Therefore, we tested the effect of BI 2536, which also inhibits
the activity of mouse Plk1 [25], on HCC progression in TGFα/c-myc
mice. Primovist-enhanced MRI was used to detect the endogenous
HCCs in TGFα/c-myc mice. HCCs were detectable 16 to 20 weeks
after beginning of the induction of the hepatocarcinogenesis. HCC
progression before the treatment was determined by two MRI mea-
surements separated by 2 weeks. After the second MRI, mice were
either treated with BI 2536 (30 mg/kg) or saline twice weekly for
4 weeks. After the end of the treatment, the animals received a further
MRI to determine posttreatment size of HCC. BI 2536 treatment
tended to reduce HCC progression in TGFα/c-myc mice, but this
did not reach statistical significance (Figure 3, A and B). After the last
MRI, the animals were killed and radiologically detected HCCs were
confirmed by macroscopic inspection as well as histopathologically.
BI 2536 had no significant effect on the body mass, hepatomegaly,
cellular and nuclear enlargement, and nuclear atypia, all of which are
characteristic of fast-growing TGFα/c-myc livers. Markers of liver func-
tion such as alanine aminotransferase and aspartate aminotransferase
were enhanced in the transgenic mice compared with an age-matched
control as reported earlier [26] but showed no significant changes on
BI 2536 treatment (data not shown).
BI 2536 Reduces Hepatocarcinogenesis in TGFα/c-myc Mice
To investigate if BI 2536 inhibits hepatocarcinogenesis in TGFα/
c-myc mice, double transgenic animals, in which hepatocarcinogenesis
had been induced for 12 weeks, were injected with BI 2536 (30 mg/kg)
twice weekly intravenously until week 16. BI 2536 treatment remark-
ably suppressed the tumorigenesis in TGFα/c-myc mice. All vehicle-
treated mice had foci of altered hepatocytes in the liver and 25% of
the vehicle-treated mice had dysplastic nodules (Table 1). Of the eight
BI 2536–treated mice, two were devoid of preneoplastic foci (Table 1).
In the BI 2536 treatment group, the number of foci per liver was half of
that in the control group (6.9 ± 2.1 compared with 13.9 ± 1.7, P < .05),
and the mean maximum focus diameter was 26% smaller (0.92 ± 0.27
compared with 1.25 ± 0.13, P < .05; Table 1). The expression of the
proliferation marker Ki-67 was positive in seven of eight animals within
the foci of vehicle-treated animals, whereas only one of eight of the
BI 2536–treated animals contained a Ki-67–positive focus in the liver
Figure 2. BI 2536 as well as AdV-Plk1 suppressed Huh-7 tumor progression in nude mice. When the tumors reached a diameter of 2 to
3 mm, 300 μl (7 × 109 pfu) of AdV-Plk1 (encoding a shRNA against Plk1), AdV control suspension, or saline was injected intravenously
into nudemice. (A) BI 2536 reduced Huh-7 tumor xenograft progression in nude mice. When the tumors reached a diameter of 2 to 3 mm,
BI 2536 (30 mg/kg) or saline was injected intravenously twice per week. Error bars represent the standard error of the mean. Asterisks
indicate a significant difference between the tumor diameters of BI 2536– or saline-treated animals (P< .05). (B) Growth curves of Huh-7
tumors after no treatment or intravenous application of AdV-Plk1 or AdV control revealed that AdV-Plk1 but not AdV control reduced tumor
progression. The differences in tumor volume between mice treated with AdV control or AdV-Plk1 were significant (P < .05) from day 3
after the treatment. Error bars represent the SD. (C) Down-regulation of Plk1 levels and occurrence of cleaved PARP fragment in sub-
cutaneous Huh-7 tumors from mice treated with AdV-Plk1. After the indicated duration postinjection of AdV control or AdV-Plk1, tumors
were excised and analyzed by anti-Plk1, anti-PARP, and anti–β-actin immunoblot analysis.
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Figure 3. Effect of BI 2536 on HCC progression in TGFα/c-myc mice determined by MRI. TGFα/c-myc mice with HCC received two MRI
separated by 2 weeks before the treatment. After the second MRI, the mice were either treated with BI 2536 (30 mg/kg) or saline twice
weekly for 4 weeks. At the end of the treatment, the animals received a third MRI. (A) Pretreatment and end-of-treatment MRI examina-
tions of a representative control (top) and a BI 2536–treated (bottom) HCC-bearing TGFα/c-mycmouse. TGFα/c-mycmice with HCC were
treated twice per week with vehicle or BI 2536 (30 mg/kg) by intravenous injection after the second MRI. Index lesions are indicated by
the arrows. (B) Quantitative analyses of the progression of HCC index lesions in BI 2536–treated (n = 5) and control animals (n = 5).
Shown are means ± standard error of the mean. There were no significant differences between the two groups.
Table 1. Effect of BI 2536 on Hepatocarcinogenesis in TGFα/c-myc Mice.
Treatment Group Incidence, % No. Foci/Liver, Means ± SE Mean Maximum Focus Diameter ± SE, mm
Preneoplastic Foci Dysplastic Nodules
Vehicle 100 (8/8)* 25 (2/8) 13.9 ± 1.7 1.25 ± 0.13
BI 2536 75 (6/8) 0 (0/8) 6.9 ± 2.1 0.92 ± 0.27
P NS NS .03 .026
The P value was calculated using Student t test for unpaired values. BI 2536 treatment of the animals reduced the number of foci per liver and the mean maximum focus diameter.
NS indicates not significant.
*The number of mice with preneoplastic foci/dysplastic nodules per total number of mice is shown in parentheses.
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(Figure 4, A and B, and Table 2). Four of eight BI 2536–treated
animals contained Ki-67–positive cells with no relation to preneoplastic
foci (Figure 4C and Table 2). These data indicated that BI 2536 sup-
pressed hepatocarcinogenesis in TGFα/c-myc mice.
Reduced Levels of BI 2536 in HCC Tissue Compared to
Normal Liver Tissue
Recent evidence from other cancer entities suggests that insuffi-
cient intratumoral drug levels might be an important cause of lack
of therapeutic efficacy [18]. To investigate if insufficient intratumoral
levels of BI 2536 could be a reason for the lack of effect of BI 2536
on the HCC in TGFα/c-myc mice, mice were injected intravenously
with BI 2536 (30 mg/kg) and the concentration of BI 2536 was de-
termined in HCC as well as normal liver tissue at various time points
after the injection by mass spectrometry. As illustrated in Figure 5A,
the concentration of BI 2536 was lower in the tumor than in the
normal liver tissue. Twelve hours after the injection, the concentra-
tion of BI 2536 in tumor was only 20% of that in the normal liver
tissue (Figure 5B).
Reduced Perfusion of Tumors Compared to Normal Liver
Tissue in TGFα/c-myc Mice
To investigate if the reduced the levels of BI 2536 in HCC com-
pared with adjacent normal liver tissue in TGFα/c-myc mice might
be due to lower drug delivery, we studied the perfusion of HCC and
adjacent normal liver tissue by contrast-enhanced MRI using the
intravascular contrast agent Glowing Galbumin-Rhodamine B. As
illustrated in Figure W4, A and B, contrast enhancement elicited by
Glowing Galbumine-Rhodamine B in HCC tissue ranged between
0.33- and 0.96-fold of the contrast enhancement in normal liver tissue
(mean value = 0.66 ± 0.24, P < .05 according to 1-tailed Student’s
t test). Analysis of cryosections of the livers by confocal laser scanning
microscopy revealed higher fluorescence signals in normal liver tissue
compared with tumor tissue (Figure W4C ). These data indicate that
HCC shows lower blood perfusion compared with normal liver tissue
in TGFα/c-myc mice.
Discussion
The development of more effective therapies against solid tumors
such as HCC is likely to profit from the identification of targets,
the inhibition of which preferentially kills malignant cells. Plk1 is a
good candidate to fulfill this condition [4]. Indeed, targeting Plk1
using both in vivo small interfering RNA delivery systems and novel
small-molecule inhibitors elicits significant reduction of the growth of
cultured tumor cells as well as of tumor progression in a number of
transplanted tumor models [8–12,25,27–34]. Moreover, although
Figure 4. BI 2536 reduces Ki-67 expression in the foci of altered
hepatocytes of livers of TGFα/c-myc mice. Male littermates of
TGFα/c-myc mice were assigned to the two treatment groups. The
animals received either BI 2536 (30 mg/kg) or PBS intravenously
twice weekly from week 12 to 16 after beginning of the zinc induc-
tion, followed by sacrificing of the animals, removal of the livers, fix-
ation of the livers in formalin, and sectioning. (A) Hematoxylin-eosin
staining. (B) Ki-67 staining of liver sections from vehicle-treated
TGFα/c-myc mouse revealed Ki-67–positive hepatocytes within a
focus of altered hepatocytes. The focus is within the light dashed
line. (C) Ki-67 staining of liver sections from BI 2536–treated TGFα/
c-mycmouse occasionally revealed Ki-67–positive hepatocytes with
no relation to foci of altered hepatocytes.
Table 2. Effect of BI 2536 on Ki-67 Expression in the Livers of TGFα/c-myc Mice.
Treatment Group Incidence, %
Ki-67 Negative or without
Relation to Foci
Ki-67 Expression within
Foci or Nodules
Vehicle 25 (2/8)* 75 (6/8)
BI 2536 87.5 (7/8) 12.5 (1/8)
P <.05 <.05
The P value was calculated using the Fisher exact test. BI 2536 treatment of the animals increased
the number of Ki-67–negative foci and foci-positive for Ki-67 but without relation to the foci.
*The number of mice with preneoplastic foci/dysplastic nodules per total number of mice is shown
in parentheses.
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complete loss of Plk1 is incompatible with cell division [35], there is
evidence that nontransformed cells require less Plk1 than tumor cells
[8–13], and Plk1 came up in synthetic lethal screens [36], rendering
Plk1 a highly interesting target in cancer. Despite these promising pre-
clinical data, the first clinical results with Plk1 inhibitors, including BI
2536, in patients with various solid cancers were disappointing [36].
Obviously, the preclinical tumor models do not appropriately model
the human therapeutic situation. Therefore, it is important to identify
tumor models that are more predictive for clinical success and may
allow the identification of the mechanisms of resistance. Comparative
studies for the efficacy of chemotherapeutics in transgenic and trans-
planted cancer models have been performed in K-ras–driven models of
pancreatic ductal adenocarcinoma and non–small cell lung cancer and
indicate that these transgenic tumor models may better reflect the
therapeutic efficacy of standard therapeutics in patients with the
corresponding malignant diseases than the nude mice models [17–19].
In the present study, we examined the efficacy of inhibition of
Plk1 for anti-HCC therapy using different HCC models. Our data
indicate that Plk1 is a promising therapeutic target in HCC, but the
therapeutic efficacy of the Plk1 inhibitor BI 2536 is compromised
by low intratumoral drug levels. We found much stronger Plk1 ex-
pression in HCC compared with normal liver tissue from the same
patient and that Plk1 inhibition by RNAi as well as the Plk1 inhib-
itor BI 2536 effectively inhibited HCC progression in cultured HCC
cells or nude mice xenografted with HCC. In contrast, there was no
significant effect of BI 2536 on HCC progression in the transgenic
HCC mouse model. Our finding that BI 2536 inhibited hepatocar-
cinogenesis indicates that insufficient systemic drug levels were unlikely
to be causative for its failure to reduce progression of manifest HCC in
the transgenic mouse model. The sensitivity of the transgenic HCC
model to BI 2536 paralleled the limited therapeutic efficacy of these
Plk1 inhibitors in early clinical studies in patients with different malig-
nancies [14,37]. Thus, it seems likely that the effect of BI 2536
in TGFα/c-myc HCC mice may better reflect the clinical efficacy of
BI 2536 and potentially other Plk1 inhibitors in HCC patients com-
pared to nude mice bearing HCC xenografts, although results with
BI 2536 in HCC patients are still lacking.
There is growing evidence that the tumor microenvironment plays
a crucial role in chemotherapy resistance [38] and that GEM tumor
models better reflect the impact of the tumor microenvironment on
chemotherapy resistance than transplanted tumor models. Thus, in a
GEM of ductal pancreatic cancer, the endogenous tumors are resis-
tant to gemcitabine, whereas the isolated cancer cells or transplants of
these cells were drug sensitive [18], indicating that the tumor stroma
confers chemotherapy resistance in this tumor model. Transplanted
tumors often lack the stromal organization and adaptation to host
immune defense that occur in tumors that arise because a slow pro-
cess of progressive genetic and epigenetic changes [39,40]. A complex
signaling cross talk between the different cell types in the tumor stroma
and the cancer cells themselves as well as the increased interstitial fluid
pressure in the tumors may contribute to the chemotherapy resistance
of malignant tumors [3,18,38,41]. Recent data suggest that bone mar-
row microenvironment confers resistance to BI 2536 in a model of
multiple myeloma [42]. The present study shows that, on intravenous
injection of BI 2536, the concentration of the drug is considerably
lower in the HCCs than in the surrounding normal liver tissue, repre-
senting a not-yet-recognized mechanism for resistance to BI 2536.
Thus, it is possible that low intratumoral drug levels contribute to
the rather limited clinical efficacy of BI 2536 observed in a number
of other malignancies. An important consequence is that the limited
clinical antitumor efficacy of BI 2536 and perhaps other Plk1 inhibitors
reported up to now does not mean that Plk1 is an unsuitable target.
If higher intratumoral drug levels can be achieved, Plk1 might be a
highly promising potentially tumor-selective target in HCC and other
malignant diseases.
The data of the present study indicate that insufficient drug deliv-
ery might be causative for the low intratumoral drug levels, because
Galbumin-enhanced MRI as well as by confocal laser scanning fluo-
rescence microscopy indicated lower blood perfusion in tumor tissue
compared with the normal liver tissue. Lower blood perfusion of
tumor compared with normal tissue has also been reported in other
cancer models [18,43].
A recent study has shown that inhibition of Plk1 suppresses hep-
atitis B virus X protein–induced transformation in an in vitro model
Figure 5. Reduced levels of BI 2536 in HCC of TGFα/c-myc mice. TGFα/c-myc mice bearing HCC (two per time point) were injected
intravenously with BI 2536 (30 mg/kg). After the indicated time, the mice were sacrificed, the liver was excised, and tissue samples
of HCC and non-HCC tissue were obtained. The amount of BI 2536 was determined in HCC as well as normal liver tissue at various time
points by mass spectrometry. (A) Levels of BI 2536 in liver and tumor tissue at different time. Bars signify means ± SD of samples from
two animals. (B) Ratio of BI 2536 content in tumor tissue to that in liver tissue. Values are means ± SD.
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of liver cancer progression [44] and that Plk1 expression is upregu-
lated in chemically induced hepatocarcinogenesis [45]. In the present
study, BI 2536 inhibited hepatocarcinogenesis in the TGFα/c-myc
mice, whereas established HCCs show only slight if any response
to this compound. In particular, we found that the number of pre-
neoplastic foci was considerably reduced in livers of BI 2536–treated
TGFα/c-myc mice and contained less Ki-67–positive cells. BI 2536 had
no significant influence on other characteristics of the fast-proliferating
TGFα/c-myc livers, including hepatomegaly, cellular and nuclear
enlargement and atypia, suggesting that Plk1 inhibition did not reduce
the increased rate of proliferation owing to the presence of the trans-
gene. Thus, it seems possible that hepatocyte regeneration required
to maintain liver function in patients with liver cirrhosis might be less
compromised by BI 2536 than hepatocarcinogenesis. Moreover, be-
cause some naturally occurring compounds inhibit Plk1 activity, a
nontoxic Plk1 inhibitor might be used for HCC chemoprevention in
patients with chronic hepatitis bearing a high risk to develop HCC.
In summary, our study shows that Plk1 is a promising target in
HCC and indicate that low intratumoral drug levels rather than un-
suitability of Plk1 as drug target may account for the low clinical
efficacy of BI 2536 and possibly other Plk1 inhibitors. Thus, the
efficacy of anti-Plk1 therapy with BI 2536 might be considerably
increased on elevation of the reduced BI 2536 levels.
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Supplementary Materials and Methods
Human Tissue Samples
HCC specimen and corresponding nontumorous liver tissues were
collected from 27 patients who underwent anatomic liver resection
(segmentectomy or subsegmentectomy). All patients provided in-
formed consent for tissue procurement, which was approved by the
local ethics committee. Tumor characteristics were confirmed histo-
logically to exclude mixed type of HCC. The tissue samples were snap
frozen and stored at −80°C until further analyses. The patients con-
sisted of 15 males and 12 females with a mean age of 63.8 years (stan-
dard deviation [SD], 12.0). Twelve patients had liver cirrhosis, three
patients had liver fibrosis, two patients were infected with hepatitis B
virus, two patients were infected with hepatitis C virus, one patient had
with both viruses, and 20 patients were not infected. Adjacent healthy
tissue from the same resected liver specimen served as normal tissue.
Protein Electrophoresis and Immunoblot Analysis
Homogenized tissue samples or cultured cells were lysed in RIPA
buffer (25 mM Tris-HCl pH 7.6, 150 mM NaCl, 1% NP-40, 1%
Na-deoxycholate, and 0.1% SDS supplemented with 10 μg/ml
leupeptin and 10 μg/ml aprotinin). Equal amounts of protein were
separated on SDS polyacrylamide gels as described previously [1].
Gel-resolved proteins were electrotransferred to nitrocellulose mem-
branes and detected with anti-Plk1 (Zymed, San Francisco, CA),
anti-cleaved PARP (Becton Dickinson, Sparks, MD), or anti–β-actin
(Sigma-Aldrich, St. Louis, MO). Antigen-antibody complexes were
visualized using appropriate horseradish peroxidase–conjugated anti-
bodies (Santa Cruz Biotechnology, Santa Cruz, CA). In cell extracts,
apoptosis was detected by anti–cleaved PARP fragment immunoblot
analysis [2].
Plk1 mRNA Quantification
Total RNA was extracted from tumor, normal tissue samples, or
cultured cells using the RNA Tissue Mini Kit (Qiagen, Hilden,
Germany). Quantitative (TaqMan) RT-PCR for Plk1 was per-
formed by Assays on Demand on an ABI 7000 System (Applied
Biosystems, Foster City, CA). Data were normalized to the mRNA
of glyceraldehyde-3-phosphate dehydrogenase coamplified with the
Plk1-mRNA.
Production of Recombinant AdVs
AdVs expressing Plk1- or control-shRNAs were generated using
the BLOCK-IT adenoviral RNAi expression system from Invitrogen,
with the exception that, instead of the intermediate pENTR/U6
vector, we subcloned the shRNA encoding DNA sequences (Plk1:
gtgcttcgagatctcggacgcggccgcgtccgagatctcgaagcactt, control hairpin:
aactgggtaagcgggcgcattgatcgatcaatgcgcccgcttacccagtttt) into pALsh/H1
[3] and pDONR, followed by recombination into the pAd/
BLOCK-iT-DEST vector. All subcloning steps were performed by
recombination using the Gateway technology. To produce AdV-LacZ,
we used the pAd/CMV/V5-GW/lacZ plasmid containing β-galactosidase
under the control of a cytomegalia virus (CMV) promoter (Invitrogen).
The pAd/BLOCK-iT-DEST and pAd/CMV/V5-GW/lacZ constructs
(approximately 34 kb) were linearized with Pac I (New England
Biolabs, Ipswich, MA) and transfected into HEK 293A cells using
Lipofectamine 2000 (Invitrogen). Adenoviral particles were harvested
by subjecting the HEK 293A cells to three freeze/thaw cycles. The
recombinant adenoviral particles were purified by a two-step CsCl
purification, filtration through a PD-10 desalting columns loaded with
Sephadex G-25 (Amersham, Uppsala, Sweden), and titered by a plaque
assay. For adenoviral infection, cells were grown to 50% to 70% conflu-
ence in 24-well plates. AdV type 5 was mixed with 300 μl of com-
plete medium to a concentration of 0.1 to 1 × 105 pfu/ml and
added to the cells. After 6 hours, the medium was replaced by com-
plete medium.
Cell Viability Assay
To determine the number of viable cells, we used the 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT,
Sigma-Aldrich) colorimetric assay [4].
Detection of Apoptosis
In cell culture experiments, apoptosis was evaluated using a Zeiss
35315 fluorescent microscope by inspection of nuclear morphology
and appearance of clear condensed chromatin characteristic of apop-
totic cells after staining with the blue fluorescent dye Hoechst 33342
(Sigma-Aldrich). This dye stains the condensed chromatin of apop-
totic cells more brightly than the chromatin of normal cells. Quan-
tification of apoptotic cells was performed on images taken from at
least four representative areas for each condition. For each condition,
at least 1400 cells were evaluated.
FACS Analysis
Cell cycle distribution was analyzed using a Becton Dickinson
FACScan apparatus (Becton-Dickinson, La Jolla, CA) and the Cell-
Quest 3.1 software as described [5]. The cells were harvested, washed
with PBS, fixed with ethanol, and stained with propidium iodide.
For each experiment, the cells were analyzed in triplicate. The integ-
rity of the cell population, the duplet discrimination, and the statis-
tical analyses were performed using the WinMDI software (http://
facs.scripps.edu/software.html).
Immunocytochemistry
To visualize cell division spindles, cells were grown on coverslips
and fixed with methanol at −20°C for 10 minutes. After fixation,
samples were washed with PBS and permeabilized with 0.01% Triton
X-100 in PBS for 30 seconds, washed again, and thereafter blocked
with 1% BSA in PBS for at least 1 hour. Coverslips were incubated for
1 hour at room temperature with anti–α-tubulin (clone B-5-1-2;
Sigma-Aldrich) 1:500 and consecutively with a secondary antibody
(Alexa Fluor 594 donkey antimouse; Invitrogen) and DAPI (Invitrogen).
After washing, the coverslips were mounted with anti-fading mount-
ing solution (Invitrogen) onto the slides. Images were taken on a
Zeiss Axioplan 2 microscope equipped with a CCD camera (Zeiss,
Oberkochen, Germany).
Immunohistochemistry
For histopathologic studies, dissected organs were fixed in 10%
buffered formalin and embedded in paraffin. Paraffin sections (3 μm)
were stained with hematoxylin-eosin, and hepatocellular lesions were
graded as foci of altered hepatocytes or adenomas.
For immunostaining, tissue sections were incubated with specific
antibodies against Ki-67 (ready-to-use; Master Diagnostica, Granada,
Spain). Antigen retrieval was performed with PT Link (Dako, Glostrup,
Denmark) in 10 mM citrate buffer, pH 6.1. The samples were then
incubated for 1 hour at room temperature with the primary antibody.
Immunostainings were performed using goat antirabbit horseradish
peroxidase (Dako) as secondary antibody. Tissue sections were
subsequently incubated with a polymer-peroxidase complex and 3,3′-
diaminobenzidine, and counterstained with hematoxylin (ChemMate,
Dako). Some sections were incubated without the primary antibody as
negative controls. Mouse intestine and embryo specimens that had pre-
viously shown a marked positivity for each antibody were also routinely
included as positive controls. Digital slides and representative pictures
of liver nodules were obtained with a Mirax scan (Zeiss).
Determination of the Levels of BI 2536 in Mouse Tissue
Eight TGFα/c-mycmice received 30 mg/kg BI 2536 intravenously.
At each of the four different time points (0.5, 2, 6, or 12 hours after
injection), two mice were terminally anesthetized and perfused with
Ringer’s solution to remove the remaining BI 2536 from the blood
vessels. Samples of liver and HCC tissue from each mouse were snap
frozen in liquid nitrogen and stored at −80°C. The concentrations of
BI 2536 in tumor and liver tissue were analyzed by mass spectrometry
by Pharmacelsus (Saarbrücken, Germany).
Determination of Blood Perfusion of Liver and HCC Tissue
in TGFα/c-myc Mice
Contrast-enhanced MRI using the intravascular contrast agent,
Glowing Galbumin-Rhodamine B (Biopal, Worcester, MA), was done
in a 3-T MRI scanner [6]. Six tumor-bearing mice were anesthetized,
and MRI images were obtained before and after intravenous injection
of 100 μl of Glowing Galbumin-Rhodamine B. The animals were
imaged in the coronal plane using a T1-weighted, 3D FLASH sequence
as described recently [6]. Contrast enhancement of tumor normal-
ized to liver was calculated using the following formula: contrast
enhancementtumor / contrast enhancementliver = signal intensitytumor
(Galbumine) − signal intensitytumor (nativ)/signal intensityliver
(Galbumine) − signal intensityliver (native). Subsequently, the mice
were sacrificed, and the livers were excised and fixed for 24 hours in
4% paraformaldehyde solution. Cryosections from each liver contain-
ing HCC and normal liver tissue were analyzed by confocal laser scan-
ning microscopy with an Olympus FluoView FV-1000 (Olympus
Europe, Hamburg, Germany). Rhodamin B fluorescence was excited
at 543 nm, and emitted light was detected from 550 nm to 650 nm.
The autofluorescence of liver tissue (excitation at 488 nm, emission at
500-530 nm) was used to visualize liver tissue.
Data Presentation and Statistical Analysis
Unless otherwise stated, all cell culture experiments were per-
formed at least on three different occasions with similar results. The
values are given as means ± SD. Data from different treatment groups
were analyzed by the Student’s t test for unpaired samples using the
SPSS 16.0 software or Fisher exact test. Values of cell viability, tumor
volume, and tumor mass were assumed to be normally distributed.
Ratios and values of the percentage of apoptotic cells and of mRNA
quantification were assumed to be log normally distributed. P < .05
was considered to indicate statistical significance (*).
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Figure W1. Plk1 is frequently overexpressed in human HCCs. 27 pairs of HCCs (T1-T27) and corresponding noncancerous liver tissues
(N1-N27) were obtained by surgery. (A) Protein was extracted from the tissue samples and was analyzed by anti-Plk1 and anti–β-actin
immunoblot analysis. (B) Determination of Plk1 mRNA by quantitative PCR. Expression levels of Plk1 mRNA were normalized against
glyceraldehyde-3-phosphate dehydrogenase. Data represent Plk1 mRNA levels in HCC tissue samples divided by the Plk1 mRNA level in
normal liver tissue of the same patient. The numbers above the columns indicate the fold Plk1 in the HCC sample of the corresponding
noncancerous tissue.
Figure W2. AdV-Plk1, but not AdV control, inhibited Plk1 expression in cultured HCC cell lines. Huh-7 cells were infected with 105 pfu/ml
or the indicated amount of AdV-Plk1 or AdV control. At 48 hours later, the cells were lysed and analyzed for Plk1 mRNA (left panel) as
well as by anti-Plk1 and anti–β-actin immunoblot analysis (right panel). Asterisks (*) indicate a significant difference between control
AdV– and AdV-Plk1–treated cells.
Figure W3. Intravenously infused AdV effectively infects Huh-7
tumors in nude mice. When the tumors reached a diameter of 2
to 3 mm, 300 μl (7 × 109 pfu) of AdV-LacZ suspension or saline
were injected intravenously. Three days later, the mice were sac-
rificed, and the tumors were excised. Cryosections were stained
with X-Gal and counterstained with Nuclear Fast Red. Pictures
were taken using a CCD camera and reveal that xenografts from
AdV-LacZ–treated animals but not from saline-treated animals
showed significant X-Gal staining. Magnification, ×200.
Figure W4. Tumors of TGFα/c-mycmice are frequently less perfused than normal liver tissue. (A) MR images of a tumor-bearing HCC before
(native) and after intravenous injection of 100 μl of Glowing Galbumine-Rhodamine B (middle panel). The right panel shows the same tumor
by Primovist-enhanced MRI 1 week before. The tumor is marked by arrows. Gallbladders are marked by asterisks. (B) Ratios of contrast
enhancement of tumor and corresponding normal liver tissue in the six TGFα/c-mycmice. Numbers 2 and 3 are two different tumors of the
same mouse. (C) Confocal laser scanning microscopy image of a cryosection from the same mice as (A) and (B). The tumor tissue (lower
right part) shows less and a more heterogeneous staining with Rhodamine B (red) compared with the normal liver tissue (upper left part).
